Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

UroGen to Present at 38th Annual J.P. Morgan Healthcare Conference


UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that Liz Barrett, President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 1:30 PM Pacific Time. The event will be held in San Francisco at the Westin St. Francis.

A live audio webcast of the event will be available on the Investors section of UroGen's website, www.urogen.com. A replay of the webcast will be available on the website for approximately two weeks.

About UroGen Pharma Ltd.

UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGeltm reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's lead investigational candidates, UGN-101 (mitomycin gel) for instillation, and UGN-102 (mitomycin gel) for intravesical instillation, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer, respectively. UroGen is headquartered in New York, NY with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.


These press releases may also interest you

at 09:55
The "Global Marine Biotechnology Market 2020-2024" report has been added to ResearchAndMarkets.com's offering. Global Marine Biotechnology Market 2020-2024 The analyst has been monitoring the global marine biotechnology market and it is poised...

at 09:47
In an effort to minimize the use of narcotics after and during surgery, Intermountain Healthcare is the first health system in Utah to establish an opioid-free surgery program for patients seeking alternative pain control methods....

at 09:41
PolyPid Ltd., a Phase 3 clinical-stage  biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that the first patient has been enrolled...

at 09:40
GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) today announced the acceptance of a regulatory submission seeking an additional indication for the use of once-daily, single-inhaler triple therapy, Trelegy Ellipta (fluticasone...

at 09:37
Specialty pharmaceutical company CMP Pharma, Inc. announced today that its Potassium Phosphates Injection, the first ever FDA Approved Potassium Phosphates Injection, was approved on September 19, 2019. This will provide Health Care Providers, for...

at 09:35
TOMI Environmental Solutions, Inc.® ("TOMI") , is a global company specializing in disinfection and decontamination, utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist products - a hydrogen peroxide-based mist and...



News published on 8 january 2020 at 08:05 and distributed by: